JAK1-IN-8

CAS No. 1973485-18-5

JAK1-IN-8( —— )

Catalog No. M34801 CAS No. 1973485-18-5

JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 37 Get Quote
10MG 68 Get Quote
25MG 135 Get Quote
50MG 242 Get Quote
100MG 402 Get Quote
200MG 538 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JAK1-IN-8
  • Note
    Research use only, not for human use.
  • Brief Description
    JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).
  • Description
    JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1973485-18-5
  • Formula Weight
    442.51
  • Molecular Formula
    C22H23FN4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (282.48 mM; Ultrasonic )
  • SMILES
    Fc1cc(ccc1CN1CCS(=O)(=O)CC1)-c1cccc2nc(NC(=O)C3CC3)cn12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jin Li, et al. Composés d'imidazo[1,2-a]pyridin-2-ylamine substitués, compositions pharmaceutiques et leurs méthodes d'utilisation. Patent WO2016119700A1.
molnova catalog
related products
  • JAK-IN-10

    JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.

  • Ifidancitinib

    Ifidancitinib (ATI-50002) is a specific JAK kinase 1/3 inhibitor that induces hair growth in AA-affected C3H/HeJ mice.Ifidancitinib can be used to study autoimmune diseases.

  • Levofloxacin

    Levofloxacin is a broad-spectrum antibiotic topoisomerase II and topoisomerase IV inhibitor, used to treat respiratory, urinary tract, gastrointestinal, and abdominal infections.